SCHEMBL3343379

SCHEMBL3343379

CCOC(=O)C1(C(=O)OCC)Oc2c(cc(F)cc2-c2ccccc2C(F)(F)F)S1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TDP1 Q9NUW8 3/20 0.35
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
ALDH1A1 P00352 3/20 0.34
GLA P06280 2/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KDM4E B2RXH2 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
MAPT P10636 1/20 0.34
GRM1 Q13255 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341784 0.85 MAPT (0.38) MEN1KMT2AALDH1A1GLACTDSP1
SCHEMBL3347640 0.66 AKR1C3 (0.39) TDP1AKR1C3AKR1C2ALDH1A1L3MBTL1
SCHEMBL3343338 0.65 AKR1C3 (0.32) TDP1AKR1C3AKR1C2ALDH1A1MAPT
SCHEMBL24017163 0.64 HSD11B1 (0.49) AKR1C3AKR1C2ALDH1A1CYP1A2CYP2C19
SCHEMBL29775825 0.63 TSHR (0.49) KMT2AALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL19814624 0.63 TSHR (0.49) KMT2AALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL3345385 0.62 HTR2C (0.34) AKR1C3AKR1C2
SCHEMBL3347490 0.62 AQP1 (0.33) MEN1KMT2AAKR1C3AKR1C2ALDH1A1
SCHEMBL11099670 0.62 MAOB (0.49) MEN1KMT2AALDH1A1L3MBTL1KDM4E
SCHEMBL1994129 0.61 TSHR (0.67) TDP1ALDH1A1L3MBTL1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160411-A1 BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF WYETH (US) 2010-06-24 US disclosed
US-20100160411-A1 BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF WYETH (US) 2010-06-24 US disclosed
US-20100160411-A1 BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF WYETH (US) 2010-06-24 US disclosed
WO-2008052078-A2 BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF WYETH (US) 2008-05-02 WO disclosed
WO-2008052078-A2 BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF WYETH (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160411-A1 BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF HTR2C, HTR3B, HTR1A MEN1 3385/4885KMT2A 2358/4885TDP1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.